Meropenem

Q: Meropenem has the advantage of no seizure risk over Imipenem?

A) True
B) False


Answer: B

There is some confusion of Meropenem's advantage over Imipenem that it is preferable due to no seizure risk. It is not proven, though the risk may be lower. The only proven advantage meropenem has over imipenem is it's broader gram-negative and anaerobe coverage. Also, it does not require co-administration with cilastatin. It can be used for bacterial meningitis.

#infectious-diseases


Reference:

Cannon JP, Lee TA, Clark NM, et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014; 69:2043.